Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. has submitted an IND application to the FDA for a Phase IIb clinical trial of Namodenoson for treating MASH, building on promising Phase IIa results. The trial aims to assess Namodenoson’s efficacy in reducing hepatic steatosis and fibrosis in MASH patients, with patient enrollment already underway in Europe and Israel. Given the increasing prevalence of MASH in the U.S. and the potential size of the market, this development is of significant interest to investors and the pharmaceutical industry.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
